J
Jean-Sebastien Diana
Researcher at University of Paris
Publications - 5
Citations - 513
Jean-Sebastien Diana is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 1, co-authored 2 publications receiving 333 citations. Previous affiliations of Jean-Sebastien Diana include Necker-Enfants Malades Hospital.
Papers
More filters
Journal ArticleDOI
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Alexis A. Thompson,Mark C. Walters,Janet L. Kwiatkowski,John E.J. Rasko,John E.J. Rasko,John E.J. Rasko,Jean-Antoine Ribeil,Suradej Hongeng,Elisa Magrin,Gary J. Schiller,Emmanuel Payen,Michaela Semeraro,Despina Moshous,François Lefrère,Hervé Puy,Philippe Bourget,Alessandra Magnani,Laure Caccavelli,Jean-Sebastien Diana,Felipe Suarez,Fabrice Monpoux,Valentine Brousse,Catherine Poirot,Catherine Poirot,Chantal Brouzes,Jean-François Meritet,Corinne Pondarré,Yves Beuzard,Stany Chrétien,Thibaud Lefebvre,David T. Teachey,Usanarat Anurathapan,P. Joy Ho,P. Joy Ho,Christof von Kalle,Morris Kletzel,Elliott Vichinsky,Sandeep Soni,Gabor Istvan Veres,Olivier Negre,Robert W. Ross,David Davidson,Alexandria Petrusich,Laura Sandler,Mohammed Asmal,Olivier Hermine,Mariane de Montalembert,Salima Hacein-Bey-Abina,Stéphane Blanche,Philippe Leboulch,Philippe Leboulch,Philippe Leboulch,Marina Cavazzana +52 more
TL;DR: Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long‐term red‐cell transfusions in 22 patients with severe β‐thalassemia without serious adverse events related to the drug product.
Journal ArticleDOI
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Elisa Magrin,Michaela Semeraro,Nicolas Hebert,Laure Joseph,Alessandra Magnani,Anne Chalumeau,Aurélie Gabrion,Cécile Roudaut,J. Marouene,François Lefrère,Jean-Sebastien Diana,Adeline Denis,Bénédicte Neven,Isabelle Funck-Brentano,Olivier Negre,Sylvain Renolleau,Valentine Brousse,Laurent Kiger,Fabien Touzot,Catherine Poirot,Philippe Bourget,Wassim El Nemer,Stéphane Blanche,Jean-Marc Tréluyer,Mohammed Asmal,Courtney E. Walls,Yves Beuzard,Manfred Schmidt,Salima Hacein-Bey-Abina,Vahid Asnafi,Isabelle Guichard,Maryline Poiree,F. Monpoux,Philippe Touraine,Chantal Brouzes,Mariane de Montalembert,Emmanuel Payen,Emmanuelle Six,Jean-Antoine Ribeil,Annarita Miccio,Pablo Bartolucci,Philippe Leboulch,Marina Cavazzana +42 more
TL;DR: Clinical remission and remediation of biological hallmarks of the disease have been sustained in two of the three patients with SCD, and frequency of transfusions was reduced in the third, and key primary endpoints included mortality, engraftment, replication-competent lentivirus and clonal dominance.
Journal ArticleDOI
Therapeutic plasma exchange for life-threatening pediatric disorders.
Jean-Sebastien Diana,Jean-Sebastien Diana,Sandra Manceau,Sandra Manceau,Tioka Rabeony,Caroline Elie,Valerie Jolaine,Sandrine Zamora,Mélodie Aubart,Nadège Salvi,Christine Bodemer,Christine Bodemer,Brigitte Bader-Meunier,Christine Barnerias,Franck Iserin,C. Chardot,C. Chardot,Florence Lacaille,Sylvain Renolleau,Sylvain Renolleau,Rémi Salomon,Rémi Salomon,Laure Joseph,Marina Cavazzana,Marina Cavazzana,François Lefrère,Laurent Dupic,Marianne Delville,Marianne Delville +28 more
TL;DR: In this paper, the authors evaluated the tolerance of TPE in pediatric patients and found that the risk of adverse events was not related to the indication for TPE, the intensity of care, venous access, plasma substitute use, or body weight.
Journal ArticleDOI
Correction to: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy
Isabelle André,Laura Simons,Kuiying Ma,Ranjita Devi Moirangthem,Jean-Sebastien Diana,Elisa Magrin,Chloé Couzin,Alessandra Magnani,Chantal Lagresle-Peyrou,Marina Cavazzana +9 more
TL;DR: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy is described.
Journal ArticleDOI
Bayesian Modeling Immune Reconstitution Apply to CD34+ Selected Stem Cell Transplantation for Severe Combined Immunodeficiency
Jean-Sebastien Diana,Naïm Bouazza,Chloé Couzin,Martin Castelle,Alessandra Magnani,Elisa Magrin,Jérémie Rosain,Jean-Marc Tréluyer,Capucine Picard,Despina Moshous,Stéphane Blanche,Bénédicte Neven,Marina Cavazzana +12 more
TL;DR: It is shown that this Bayesian modeling approach predicted the time course and extent of CD4+ T-cell immune reconstitution after SCID transplantation.